ArticleEuropean journal of cancer (Oxford, England : 1990)2022
Incorporating progesterone receptor expression into the PREDICT breast prognostic model.
Abstract read
In one paragraph
Article in European journal of cancer (Oxford, England : 1990), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Methodological guidance for the evaluation and updating of clinical prediction models: a systematic review.BMC medical research methodology · 2022Pooled it
- Overall survival and prognostic factors in young women with breast cancer: a retrospective cohort study from Southern Thailand.World journal of surgical oncology · 2026Article
- Validation of the postoperative prognostication tool PREDICT version 2.2 and 3.0 using data from the National cancer center hospital in Japan.Breast cancer (Tokyo, Japan) · 2026Article
- Validation of PREDICT tool v2.2 in patients with early-stage breast cancer enrolled in the GIM and MIG trials.ESMO open · 2026Article
- PREDICT breast v4.0: an update to the PREDICT breast prognostic model.BMC research notes · 2025Article
- Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of Recurrence.Geburtshilfe und Frauenheilkunde · 2024Article
- Expression of transglutaminase-2 (TGM2) in the prognosis of female invasive breast cancer.BJC reports · 2024Article
- Evaluation of Predict, a prognostic risk tool, after diagnosis of a second breast cancer.JNCI cancer spectrum · 2023Article
- The use and misuse of risk prediction tools for clinical decision-making.Breast (Edinburgh, Scotland) · 2023Article
- PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants.NPJ breast cancer · 2023Article
- Nomograms for Predicting Disease-Free Survival Based on Core Needle Biopsy and Surgical Specimens in Female Breast Cancer Patients with Non-Pathological Complete Response to Neoadjuvant Chemotherapy.Journal of personalized medicine · 2023Article
- Development and validation of an extended Cox prognostic model for patients with ER/PR+ and HER2- breast cancer: a retrospective cohort study.World journal of surgical oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
105 authors.
Isabelle GrootesUniversity of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, CB1 8RN, UK. Electronic address: ig345@medschl.cam.ac.uk.
Renske KeemanThe Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Division of Molecular Pathology, Amsterdam, 1066 CX, the Netherlands.
Fiona M BlowsUniversity of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, CB1 8RN, UK.
Roger L MilneCancer Council Victoria, Cancer Epidemiology Division, Melbourne, Victoria, 3004, Australia; The University of Melbourne, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, Melbourne, Victoria, 3010, Australia; Monash University, Precision Medicine, School of Clinical Sciences at Monash Health, Clayton, Victoria, 3168, Australia.
Graham G GilesCancer Council Victoria, Cancer Epidemiology Division, Melbourne, Victoria, 3004, Australia; The University of Melbourne, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, Melbourne, Victoria, 3010, Australia; Monash University, Precision Medicine, School of Clinical Sciences at Monash Health, Clayton, Victoria, 3168, Australia.
Anthony J SwerdlowThe Institute of Cancer Research, Division of Genetics and Epidemiology, London, SM2 5NG, UK; The Institute of Cancer Research, Division of Breast Cancer Research, London, SW7 3RP, UK.
Peter A FaschingUniversity of California at Los Angeles, David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, Los Angeles, CA, 90095, USA; Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU), Department of Gynecology and Obstetrics, Erlangen, 91054, Germany.
Mustapha AbubakarNational Cancer Institute, National Institutes of Health, Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, Bethesda, MD, 20850, USA.
Irene L AndrulisLunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Fred A. Litwin Center for Cancer Genetics, Toronto, ON, M5G 1X5, Canada; University of Toronto, Department of Molecular Genetics, Toronto, ON, M5S 1A8, Canada.
Hoda Anton-CulverUniversity of California Irvine, Department of Medicine, Genetic Epidemiology Research Institute, Irvine, CA, 92617, USA.
Matthias W BeckmannComprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU), Department of Gynecology and Obstetrics, Erlangen, 91054, Germany.
Carl BlomqvistUniversity of Helsinki, Department of Oncology, Helsinki University Hospital, Helsinki, 00290, Finland; Örebro University Hospital, Department of Oncology, Örebro, 70185, Sweden.
Stig E BojesenCopenhagen University Hospital, Copenhagen General Population Study, Herlev and Gentofte Hospital, Herlev, 2730, Denmark; Copenhagen University Hospital, Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Herlev, 2730, Denmark; University of Copenhagen, Faculty of Health and Medical Sciences, Copenhagen, 2200, Denmark.
Manjeet K BollaUniversity of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, CB1 8RN, UK.
Bernardo BonanniIEO, European Institute of Oncology IRCCS, Division of Cancer Prevention and Genetics, Milan, 20141, Italy.
Ignacio BricenoUniversidad de La Sabana, Medical Faculty, Bogota, 140013, Colombia.
Barbara BurwinkelGerman Cancer Research Center (DKFZ), Molecular Epidemiology Group, C080, Heidelberg, 69120, Germany; University of Heidelberg, Molecular Biology of Breast Cancer, University Womens Clinic Heidelberg, Heidelberg, 69120, Germany.
Nicola J CampUniversity of Utah, Department of Internal Medicine and Huntsman Cancer Institute, Salt Lake City, UT, 84112, USA.
Jose E CastelaoInstituto de Investigación Sanitaria Galicia Sur (IISGS), Xerencia de Xestion Integrada de Vigo-SERGAS, Oncology and Genetics Unit, Vigo, 36312, Spain.
Ji-Yeob ChoiSeoul National University Graduate School, Department of Biomedical Sciences, Seoul, 03080, South Korea; Seoul National University, Cancer Research Institute, Seoul, 03080, South Korea; Seoul National University Medical Research Center, Institute of Health Policy and Management, Seoul, 03080, South Korea.
Christine L ClarkeUniversity of Sydney, Westmead Institute for Medical Research, Sydney, New South Wales, 2145, Australia.
Fergus J CouchMayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN, 55905, USA.
Angela CoxUniversity of Sheffield, Sheffield Institute for Nucleic Acids (SInFoNiA), Department of Oncology and Metabolism, Sheffield, S10 2TN, UK.
Simon S CrossUniversity of Sheffield, Academic Unit of Pathology, Department of Neuroscience, Sheffield, S10 2TN, UK.
Kamila CzeneKarolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, 171 65, Sweden.
Peter DevileeLeiden University Medical Center, Department of Pathology, Leiden, 2333 ZA, the Netherlands; Leiden University Medical Center, Department of Human Genetics, Leiden, 2333 ZA, the Netherlands.
Thilo DörkHannover Medical School, Gynaecology Research Unit, Hannover, 30625, Germany.
Alison M DunningUniversity of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, CB1 8RN, UK.
Miriam DwekUniversity of Westminster, School of Life Sciences, London, W1B 2HW, UK.
Douglas F EastonUniversity of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, CB1 8RN, UK; University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, CB1 8RN, UK.
Diana M EcclesUniversity of Southampton, Faculty of Medicine, Southampton, SO17 1BJ, UK.
Mikael ErikssonKarolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, 171 65, Sweden.
Kristina ErnstUniversity Hospital Ulm, Department of Gynaecology and Obstetrics, Ulm, 89075, Germany.
D Gareth EvansUniversity of Manchester, Manchester Academic Health Science Centre, Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester, M13 9WL, UK; St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, North West Genomics Laboratory Hub, Manchester Centre for Genomic Medicine, Manchester, M13 9WL, UK.
Jonine D FigueroaNational Cancer Institute, National Institutes of Health, Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, Bethesda, MD, 20850, USA; The University of Edinburgh, Usher Institute of Population Health Sciences and Informatics, Edinburgh, EH16 4UX, UK; The University of Edinburgh, Cancer Research UK Edinburgh Centre, Edinburgh, EH4 2XR, UK.
Visnja FinkUniversity Hospital Ulm, Department of Gynaecology and Obstetrics, Ulm, 89075, Germany.
Giuseppe FlorisLeuven Cancer Institute, University Hospitals Leuven, Leuven Multidisciplinary Breast Center, Department of Oncology, Leuven, 3000, Belgium.
Stephen FoxPeter MacCallum Cancer Center, Melbourne, Victoria, Australia, 3000.
Marike GabrielsonKarolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, 171 65, Sweden.
Manuela Gago-DominguezInstituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, SERGAS, Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, 15706, Spain; University of California San Diego, Moores Cancer Center, La Jolla, CA, 92037, USA.
José A García-SáenzInstituto de Investigación Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica en Red de Cáncer (CIBERONC), Medical Oncology Department, Hospital Clínico San Carlos, Madrid, 28040, Spain.
Anna González-NeiraSpanish National Cancer Research Centre (CNIO), Human Cancer Genetics Programme, Madrid, 28029, Spain.
Lothar HaeberleComprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU), Department of Gynecology and Obstetrics, Erlangen, 91054, Germany.
Christopher A HaimanUniversity of Southern California, Department of Preventive Medicine, Keck School of Medicine, Los Angeles, CA, 90033, USA.
Per HallKarolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, 171 65, Sweden; Södersjukhuset, Department of Oncology, Stockholm, 118 83, Sweden.
Ute HamannGerman Cancer Research Center (DKFZ), Molecular Genetics of Breast Cancer, Heidelberg, 69120, Germany.
Elaine F HarknessUniversity of Manchester, Manchester Academic Health Science Centre, Division of Informatics, Imaging and Data Sciences, Faculty of Biology, Medicine and Health, Manchester, M13 9PT, UK; Wythenshawe Hospital, Manchester University NHS Foundation Trust, Nightingale & Genesis Prevention Centre, Manchester, M23 9LT, UK; Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Unit, Manchester, M13 9WL, UK.
Mikael HartmanNational University of Singapore and National University Health System, Saw Swee Hock School of Public Health, Singapore, 119077, Singapore; National University Health System, Department of Surgery, Singapore, 119228, Singapore.
Alexander HeinComprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg (FAU), Department of Gynecology and Obstetrics, Erlangen, 91054, Germany.
Maartje J HooningErasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, 3015 GD, the Netherlands.
Ming-Feng HouKaohsiung Municipal Hsiao-Kang Hospital, Department of Surgery, Kaohsiung, 812, Taiwan.
Sacha J HowellUniversity of Manchester, Division of Cancer Sciences, Manchester, M13 9PL, UK.
ABCTB InvestigatorsUniversity of Sydney, Australian Breast Cancer Tissue Bank, Westmead Institute for Medical Research, Sydney, New South Wales, 2145, Australia.
kConFab InvestigatorsPeter MacCallum Cancer Center, Research Department, Melbourne, Victoria, Australia, 3000; The University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, Victoria, 3000, Australia.
Hidemi ItoAichi Cancer Center Research Institute, Division of Cancer Information and Control, Nagoya, 464-8681, Japan; Nagoya University Graduate School of Medicine, Division of Cancer Epidemiology, Nagoya, 466-8550, Japan.
Anna JakubowskaPomeranian Medical University, Department of Genetics and Pathology, Szczecin, 71-252, Poland; Pomeranian Medical University, Independent Laboratory of Molecular Biology and Genetic Diagnostics, Szczecin, 71-252, Poland.
Wolfgang JanniUniversity Hospital Ulm, Department of Gynaecology and Obstetrics, Ulm, 89075, Germany.
Esther M JohnStanford University School of Medicine, Department of Epidemiology & Population Health, Stanford, CA, 94305, USA; Stanford Cancer Institute, Stanford University School of Medicine, Department of Medicine, Division of Oncology, Stanford, CA, 94304, USA.
Audrey JungGerman Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, 69120, Germany.
Daehee KangSeoul National University, Cancer Research Institute, Seoul, 03080, South Korea; Seoul National University College of Medicine, Department of Preventive Medicine, Seoul, 03080, South Korea.
Vessela N KristensenOslo University Hospital and University of Oslo, Department of Medical Genetics, Oslo, 0379, Norway; University of Oslo, Institute of Clinical Medicine, Faculty of Medicine, Oslo, 0450, Norway.
Ava KwongHong Kong Hereditary Breast Cancer Family Registry, Hong Kong; The University of Hong Kong, Department of Surgery, Hong Kong; Hong Kong Sanatorium and Hospital, Department of Surgery and Cancer Genetics Center, Hong Kong.
Diether LambrechtsVIB Center for Cancer Biology, VIB, Leuven, 3001, Belgium; University of Leuven, Laboratory for Translational Genetics, Department of Human Genetics, Leuven, 3000, Belgium.
Jingmei LiGenome Institute of Singapore, Human Genetics Division, Singapore, 138672, Singapore.
Jan LubińskiPomeranian Medical University, Department of Genetics and Pathology, Szczecin, 71-252, Poland.
Mehdi ManoochehriGerman Cancer Research Center (DKFZ), Molecular Genetics of Breast Cancer, Heidelberg, 69120, Germany.
Sara MargolinSödersjukhuset, Department of Oncology, Stockholm, 118 83, Sweden; Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset, Stockholm, 118 83, Sweden.
Keitaro MatsuoNagoya University Graduate School of Medicine, Division of Cancer Epidemiology, Nagoya, 466-8550, Japan; Aichi Cancer Center Research Institute, Division of Cancer Epidemiology and Prevention, Nagoya, 464-8681, Japan.
Nur Aishah Mohd TaibUniversity of Malaya, Department of Surgery, Faculty of Medicine, Kuala Lumpur, 50603, Malaysia.
Anna Marie MulliganUniversity of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, ON, M5S 1A8, Canada; University Health Network, Laboratory Medicine Program, Toronto, ON, M5G 2C4, Canada.
Heli NevanlinnaUniversity of Helsinki, Department of Obstetrics and Gynecology, Helsinki University Hospital, Helsinki, 00290, Finland.
William G NewmanUniversity of Manchester, Manchester Academic Health Science Centre, Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester, M13 9WL, UK; St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, North West Genomics Laboratory Hub, Manchester Centre for Genomic Medicine, Manchester, M13 9WL, UK.
Kenneth OffitMemorial Sloan Kettering Cancer Center, Clinical Genetics Research Lab, Department of Cancer Biology and Genetics, New York, NY, 10065, USA; Memorial Sloan Kettering Cancer Center, Clinical Genetics Service, Department of Medicine, New York, NY, 10065, USA.
Ana OsorioSpanish National Cancer Research Centre (CNIO), Human Cancer Genetics Programme, Madrid, 28029, Spain; Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, 28029, Spain.
Sue K ParkSeoul National University, Cancer Research Institute, Seoul, 03080, South Korea; Seoul National University College of Medicine, Department of Preventive Medicine, Seoul, 03080, South Korea; Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul, 03080, South Korea.
Tjoung-Won Park-SimonHannover Medical School, Gynaecology Research Unit, Hannover, 30625, Germany.
Alpa V PatelAmerican Cancer Society, Department of Population Science, Atlanta, GA, 30303, USA.
Nadege PresneauUniversity of Westminster, School of Life Sciences, London, W1B 2HW, UK.
Katri PylkäsUniversity of Oulu, Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, Biocenter Oulu, Oulu, 90570, Finland; Northern Finland Laboratory Centre Oulu, Laboratory of Cancer Genetics and Tumor Biology, Oulu, 90570, Finland.
Brigitte RackUniversity Hospital Ulm, Department of Gynaecology and Obstetrics, Ulm, 89075, Germany.
Paolo RadiceFondazione IRCCS Istituto Nazionale dei Tumori (INT), Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Milan, 20133, Italy.
Gad RennertCarmel Medical Center and Technion Faculty of Medicine, Clalit National Cancer Control Center, Haifa, 35254, Israel.
Atocha RomeroHospital Universitario Puerta de Hierro, Medical Oncology Department, Madrid, 28222, Spain.
Emmanouil SaloustrosUniversity Hospital of Larissa, Department of Oncology, Larissa, 411 10, Greece.
Elinor J SawyerKing's College London, School of Cancer & Pharmaceutical Sciences, Comprehensive Cancer Centre, Guy's Campus, London, UK.
Andreas SchneeweissUniversity of Heidelberg, Molecular Biology of Breast Cancer, University Womens Clinic Heidelberg, Heidelberg, 69120, Germany; University Hospital and German Cancer Research Center, National Center for Tumor Diseases, Heidelberg, 69120, Germany.
Fabienne SchochterUniversity Hospital Ulm, Department of Gynaecology and Obstetrics, Ulm, 89075, Germany.
Minouk J SchoemakerThe Institute of Cancer Research, Division of Genetics and Epidemiology, London, SM2 5NG, UK.
Chen-Yang ShenAcademia Sinica, Institute of Biomedical Sciences, Taipei, 115, Taiwan; China Medical University, School of Public Health, Taichung, Taiwan.
Rana ShibliCarmel Medical Center and Technion Faculty of Medicine, Clalit National Cancer Control Center, Haifa, 35254, Israel.
Peter SinnUniversity Hospital Heidelberg, Department of Pathology, Institute of Pathology, Heidelberg, 69120, Germany.
William J TapperUniversity of Southampton, Faculty of Medicine, Southampton, SO17 1BJ, UK.
Essa TawfiqUniversity of Auckland, Auckland, New Zealand.
Soo Hwang TeoUniversity of Malaya, Department of Surgery, Faculty of Medicine, Kuala Lumpur, 50603, Malaysia; Cancer Research Malaysia, Breast Cancer Research Programme, Subang Jaya, Selangor, 47500, Malaysia.
Lauren R TerasAmerican Cancer Society, Department of Population Science, Atlanta, GA, 30303, USA.
Diana TorresGerman Cancer Research Center (DKFZ), Molecular Genetics of Breast Cancer, Heidelberg, 69120, Germany; Pontificia Universidad Javeriana, Institute of Human Genetics, Bogota, 110231, Colombia.
Celine M VachonMayo Clinic, Department of Quantitative Health Sciences, Division of Epidemiology, Rochester, MN, 55905, USA.
Carolien H M van DeurzenErasmus University Medical Center, Department of Pathology, Rotterdam, 3015 CN, the Netherlands.
Camilla WendtKarolinska Institutet, Department of Clinical Science and Education, Södersjukhuset, Stockholm, 118 83, Sweden.
Justin A WilliamsUniversity of Utah, Department of Internal Medicine and Huntsman Cancer Institute, Salt Lake City, UT, 84112, USA.
Robert WinqvistUniversity of Oulu, Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, Biocenter Oulu, Oulu, 90570, Finland; Northern Finland Laboratory Centre Oulu, Laboratory of Cancer Genetics and Tumor Biology, Oulu, 90570, Finland.
Mark ElwoodUniversity of Auckland, Auckland, New Zealand.
Marjanka K SchmidtThe Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Division of Molecular Pathology, Amsterdam, 1066 CX, the Netherlands; The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Division of Psychosocial Research and Epidemiology, Amsterdam, 1066 CX, the Netherlands.
Montserrat García-ClosasNational Cancer Institute, National Institutes of Health, Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, Bethesda, MD, 20850, USA.
Paul D P PharoahUniversity of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Oncology, Cambridge, CB1 8RN, UK; University of Cambridge, Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Cambridge, CB1 8RN, UK.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MHormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5MStudy of Genetic Mutation Carriage in Chinese Populations with Breast CancerR03CA130065 · NCI · CANCER PREVENTION INSTIT OF CALIFORNIA · PI WEST, DEE WAYNE · 2007 to 2008
$126kCancer Research UK 16561NCI NIH HHS P30 CA008748NCI NIH HHS R03 CA130065Wellcome Trust 203477/Z/16/Z
Abstract
backgroundPredict Breast (www.predict.nhs.uk) is an online prognostication and treatment benefit tool for early invasive breast cancer. The aim of this study was to incorporate the prognostic effect of progesterone receptor (PR) status into a new version of PREDICT and to compare its performance to the current version (2.2).
methodThe prognostic effect of PR status was based on the analysis of data from 45,088 European patients with breast cancer from 49 studies in the Breast Cancer Association Consortium. Cox proportional hazard models were used to estimate the hazard ratio for PR status. Data from a New Zealand study of 11,365 patients with early invasive breast cancer were used for external validation. Model calibration and discrimination were used to test the model performance.
resultsHaving a PR-positive tumour was associated with a 23% and 28% lower risk of dying from breast cancer for women with oestrogen receptor (ER)-negative and ER-positive breast cancer, respectively. The area under the ROC curve increased with the addition of PR status from 0.807 to 0.809 for patients with ER-negative tumours (p = 0.023) and from 0.898 to 0.902 for patients with ER-positive tumours (p = 2.3 × 10
conclusionThe inclusion of the prognostic effect of PR status to PREDICT Breast has led to an improvement of model performance and more accurate absolute treatment benefit predictions for individual patients. Further studies should determine whether the baseline hazard function requires recalibration.
Indexed as
Breast NeoplasmsReceptors, ProgesteroneErb-b2 Receptor Tyrosine KinasesFemaleHumansProgesteronePrognosisErb-b2 Receptor Tyrosine KinasesProgesteroneReceptors, Progesteronebreast cancerPREDICT BreastProgesterone receptorPrognosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.